Patents by Inventor Brian Fox

Brian Fox has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method and apparatus to facilitate self-testing of a system on chip
    Patent number: 7117416
    Abstract: A method and apparatus for providing a system-on-a-chip comprising a processor and a configurable system logic (CSL) including a plurality of banks arranged in an array coupled to the processor. The system on a chip further includes a built-in self test (BIST) mechanism coupled to the CSL to perform tests on the CSL to verify that the banks and interconnections between the banks are functioning properly.
    Type: Grant
    Filed: December 23, 2004
    Date of Patent: October 3, 2006
    Assignee: Xilinx, Inc.
    Inventor: Brian Fox
  • Configuration in a configurable system on a chip
    Patent number: 7085858
    Abstract: The present invention allows a user to customize the configuration sequence of a configurable system on a chip (CSoC), thereby adding considerable flexibility to the configuration process. The present invention also provides certain features, transparent to the user, which optimize system resources and ensure the correct initialization of the CSoC. The CSoC leverages an on-chip central processing unit (CPU) to control the configuration process of the configurable system logic (CSL). Advantageously, the CSL configuration memory cells as well as other programmable locations in the CSoC are addressable as part of a system bus address space. The system bus is a multi-use structure that can be used for both configuring and reading of memory cells. In this manner, the CSoC optimizes system resources.
    Type: Grant
    Filed: December 16, 2004
    Date of Patent: August 1, 2006
    Assignee: Xilinx, Inc.
    Inventors: Brian Fox, Andreas Papaliolios
  • Method of and system for transmitting a mobile agent for instruction execution
    Publication number: 20060165030
    Abstract: A method of executing programmable instructions includes receiving at a device a mobile agent from a mobile agent dispatching device. The mobile agent includes a state of a virtual machine. The method also includes executing at the device one or more instructions identified by the mobile agent, thereby changing the state of the virtual machine.
    Type: Application
    Filed: December 7, 2004
    Publication date: July 27, 2006
    Inventors: Brian Fox, Jonathan Lei
  • Peptide and polypeptide inhibitors of complement C1s
    Patent number: 7071299
    Abstract: The complement system plays an important role in providing resistance to infections and in the pathogenesis of tissue injury. Yet an inappropriate activation of complement can result in a variety of disorders. The present invention provides C1s catalytic site-directed moieties, C1s exosite binding moieties, and bivalent polypeptide inhibitors comprising such moieties, which can be used to treat conditions characterized by inappropriate complement activation.
    Type: Grant
    Filed: June 18, 2001
    Date of Patent: July 4, 2006
    Assignee: ZymoGenetics, Inc.
    Inventors: Robert R. West, Paul O. Sheppard, Brian A. Fox
  • Method of and instruction set for executing operations on a device
    Publication number: 20060123396
    Abstract: A method for executing operations on a device includes executing one or more bytecode language instructions associated with a mobile agent. The mobile agent includes a state of a virtual machine and the bytecode language includes instructions such WARP, MESG; ESEL, ALERT, BROWSE, CAPS, SLEEP, and GPS.
    Type: Application
    Filed: December 7, 2004
    Publication date: June 8, 2006
    Inventors: Brian Fox, Jonathan Lei
  • Cytokine protein family
    Patent number: 7038032
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for zcyto20, zcyto21, zcyto22, zycto24, and zcyto25 proteins which are most closely related to interferon-? at the amino acid sequence level. The receptor for this protein family is a class II cytokine receptor. The present invention includes methods of reducing viral infections and increasing monocyte counts. The present invention also includes antibodies to the zcyto20 polypeptides, and methods of producing the polynucleotides and polypeptides.
    Type: Grant
    Filed: April 19, 2002
    Date of Patent: May 2, 2006
    Assignee: ZymoGenetics, Inc.
    Inventors: Paul O. Sheppard, Brian A. Fox, Kevin M. Klucher, David W. Taft, Wayne Kindsvogel
  • Cytokine protein family
    Publication number: 20060063233
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for zcyto20, zcyto21, zcyto22, zycto24, and zcyto25 proteins which are most closely related to interferon-? at the amino acid sequence level. The receptor for this protein family is a class II cytokine receptor. The present invention includes methods of reducing viral infections and increasing monocyte counts. The present invention also includes antibodies to the zcyto20 polypeptides, and methods of producing the polynucleotides and polypeptides.
    Type: Application
    Filed: November 3, 2005
    Publication date: March 23, 2006
    Inventors: Paul Sheppard, Brian Fox, Kevin Klucher, David Taft, Wayne Kindsvogel
  • Adipocyte complement related protein zacrp13
    Publication number: 20050282256
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for zacrp13, a novel member of the family of proteins bearing a collagen-like domain and a C1q domain. Novel zacrp13 polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. Also disclosed are antibodies to the zacrp13 protein or fragments thereof.
    Type: Application
    Filed: August 9, 2005
    Publication date: December 22, 2005
    Inventors: Brian Fox, James Holloway
  • Peptide and polypeptide inhibitors of complement C1s
    Publication number: 20050267035
    Abstract: The complement system plays an important role in providing resistance to infections and in the pathogenesis of tissue injury. Yet an inappropriate activation of complement can result in a variety of disorders. The present invention provides C1s catalytic site-directed moieties, C1s exosite binding moieties, and bivalent polypeptide inhibitors comprising such moieties, which can be used to treat conditions characterized by inappropriate complement activation.
    Type: Application
    Filed: June 20, 2005
    Publication date: December 1, 2005
    Inventors: Robert West, Paul Sheppard, Brian Fox
  • Dimeric fusion proteins and materials and methods for producing them
    Publication number: 20050260716
    Abstract: Polypeptide fusions, dimeric fusion proteins, and materials and methods for making them are disclosed. One of the polypeptide fusions consists of a non-immunoglobulin polypeptide, a polypeptide linker, a dimerizing domain, and, optionally, a linking polypeptide. Another of the polypeptide fusions consists of a non-immunoglobulin polypeptide, a polypeptide linker, and a second dimerizing domain.
    Type: Application
    Filed: March 8, 2005
    Publication date: November 24, 2005
    Inventors: Margaret Moore, Brian Fox
  • Ztnfr14, a tumor necrosis factor receptor
    Publication number: 20050256041
    Abstract: Novel tumor necrosis factor receptor (TNFR) polypeptides, polynucleotides encoding the polypeptides, antibodies and related compositions and methods are disclosed. The polypeptides may be used for detecting ligand, as well as agonists and antagonists. The polypeptides, polynucleotides and antibodies may also be used in methods that modulate tumor growth, metastasis, and immunity such as separating resting from stimulated immune cells.
    Type: Application
    Filed: October 18, 2004
    Publication date: November 17, 2005
    Inventors: Brian Fox, James Holloway, Paul Sheppard, Stacey Dillon
  • Ztnf12, a tumor necrosis factor
    Publication number: 20050255496
    Abstract: Novel tumor necrosis factor ligand polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides may be used within methods relating to immune response, and may also be used in the development of immuno-regulatory therapeutics. Also provided are antibodies, binding proteins, agonists and antagonists of the ligand polypeptides.
    Type: Application
    Filed: December 15, 2004
    Publication date: November 17, 2005
    Inventors: Zeren Gao, Paul Sheppard, Brian Fox, James Holloway, Stephen Jaspers
  • Ztnf11, a tumor necrosis factor
    Publication number: 20050255560
    Abstract: Novel tumor necrosis factor ligand polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides may be used within methods relating to immune response, and may also be used in the development of immuno-regulatory therapeutics. Also provided are antibodies, binding proteins, agonists and antagonists of the ligand polypeptides.
    Type: Application
    Filed: November 22, 2004
    Publication date: November 17, 2005
    Inventors: Zeren Gao, Paul Sheppard, Brian Fox, James Holloway, Stephen Jaspers
  • Peptide hormones zalpha48 and zsig97
    Publication number: 20050250184
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for zalpha48 and zsig97, two proteins that define a novel peptide hormone family. The DNA encoding the peptides and the encoded peptides are useful in treating disorders of the thyroid, prostate, neural dysfunction, immune dysfunction, diseases of the pancreas, adrenal gland, ovary, and pituitary. The present invention also includes methods for producing the protein, uses therefor and antibodies therefore.
    Type: Application
    Filed: November 24, 2004
    Publication date: November 10, 2005
    Inventors: Paul Sheppard, Brian Fox
  • Ztnf13, a tumor necrosis factor
    Publication number: 20050250126
    Abstract: Novel tumor necrosis factor ligand polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides may be used within methods relating to immune response, and may also be used in the development of immuno-regulatory therapeutics. Also provided are antibodies, binding proteins, agonists and antagonists of the ligand polypeptides.
    Type: Application
    Filed: December 16, 2004
    Publication date: November 10, 2005
    Inventors: Zeren Gao, Paul Sheppard, Brian Fox, James Holloway, Stephen Jaspers, Mark Appleby
  • Adipocyte complement related protein zacrp13
    Patent number: 6955899
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for zacrp13, a novel member of the family of proteins bearing a collagen-like domain and a C1q domain. Novel zacrp13 polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. Also disclosed are antibodies to the zacrp13 protein or fragments thereof.
    Type: Grant
    Filed: October 17, 2003
    Date of Patent: October 18, 2005
    Assignee: ZymoGenetics, Inc.
    Inventors: Brian A. Fox, James L. Holloway
  • Fluorescence polarization assay to detect protease cleavage
    Publication number: 20050227306
    Abstract: The invention discloses a method of determining protease activity, in real time, using fluorescence polarization technology. In particular, the invention provides vectors and a method for their use, which expresses uncharacterized proteins conjugated to a fluorescence tag, which binds specifically to a fluorescent ligand. Cleavage of the recombinant protein results in a fragment of the expressed peptide and results in a change in fluorescence polarization of the fluorophore. The rate of change in fluorescence polarization can be measured in real time and is equivalent to the rate of protease cleavage.
    Type: Application
    Filed: November 24, 2004
    Publication date: October 13, 2005
    Inventors: Brian Fox, Paul Blommel
  • Kunitz domain polypeptide Zkun10
    Publication number: 20050176105
    Abstract: Proteinase inhibitors comprising a Kunitz domain are disclosed. The Kunitz domain comprises a motif of amino acid residues as shown in SEQ ID NO:4, and the sequence of the Kunitz domain is shown in residues 57 through 107 of SEQ ID NO:2. The polypeptide also includes an N-terminal collagen domain in which a von Willebrand domain resides, and is shown in SEQ ID NO: 5. Also disclosed are methods for making the proteinase inhibitors, and expression vectors and cultured cells that are useful within the methods. The proteinase inhibitors may be used as components of cell culture media, in protein purification, and as inhibitors of protease degradation of plasma proteins.
    Type: Application
    Filed: March 16, 2005
    Publication date: August 11, 2005
    Inventors: Paul Sheppard, Brian Fox
  • Interferon-like protein Zcyto21
    Patent number: 6927040
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-? at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypeptides, and methods of using the polynucleotides and polypeptides.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: August 9, 2005
    Assignee: ZymoGenetics, Inc.
    Inventors: Paul O. Sheppard, Scott R. Presnell, Brian A. Fox, Teresa Gilbert, Betty A. Haldeman, Francis J. Grant
  • Kunitz domain polypeptide zkun10
    Patent number: 6914135
    Abstract: Proteinase inhibitors comprising a Kunitz domain are disclosed. The Kunitz domain comprises a motif of amino acid residues as shown in SEQ ID NO:4, and the sequence of the Kunitz domain is shown in residues 57 through 107 of SEQ ID NO:2. The polypeptide also includes an N-terminal collagen domain in which a von Willebrand domain resides, and is shown in SEQ ID NO: 5. Also disclosed are methods for making the proteinase inhibitors, and expression vectors and cultured cells that are useful within the methods. The proteinase inhibitors may be used as components of cell culture media, in protein purification, and as inhibitors of protease degradation of plasma proteins.
    Type: Grant
    Filed: December 9, 2002
    Date of Patent: July 5, 2005
    Assignee: ZymoGenetics, Inc.
    Inventors: Paul O. Sheppard, Brian A. Fox